Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from April 14, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on July 13, 2026 — +26.5% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$37.40 – $38.40Entry zone — fair-value band

$38.95Published — price the day we called it

$43.23Target — the price the thesis aimed for

$50.90Peak — highest point inside the window, not a realized return

$49.28Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 17 days.

At window close

+26.5%

realized, from the publication price to the last close inside the window

Peak gain

+30.7%

peak, from the publication price — not a realized return

S&P 500, same window

+8.2%

SPY over the identical days, dividend-adjusted

Window close

$49.28

last close inside the window, ended July 13, 2026

Peak price

$50.90

peak on July 2, 2026 — not a realized return

Days to target

The thesis — published April 14, 2026

Predicted growth

+11%

over the measurement window

Target price

$43.23

the price the thesis aimed for

Entry zone

$37.40 – $38.40

the fair-value band we waited for

Price at publication

$38.95

published April 14, 2026

Confidence

67%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk looks like a safer growth choice for the next few months because its main products are steady sellers and the stock moves less wildly than many peers. News is mixed: a new OpenAI tie could make drug research cheaper and faster, but a big fund selling some shares raises questions about near-term visibility. Slowing business momentum and a rebound that is already advanced justify caution.

Primary drivers

OpenAI tie may speed research and reduce costs
Less volatile healthcare stock can steady a portfolio in choppy markets
Large diabetes and obesity franchises provide steady revenue
Conflicting signals from news argue for a cautious stance

How it played out

NVO: target reached in 17 days

Lyra published NVO at 38.95 on April 14, with an 11% expected gain and a 43.23 target. The thesis pointed to steady sales from its diabetes and obesity franchises, lower volatility than many peers, and a cautious mix of signals. It also cited a technology partnership as a way to speed research and reduce costs.

Inside the window, NVO reached the target in 17 days. It later peaked at 50.90 on July 2, a 30.7% gain, and ended at 49.28 on July 13. The peak and closing price both cleared 43.23. The published thesis played out.

What happened during the window

On April 14, Novo Nordisk announced a technology partnership focused on drug discovery and commercial operations. On June 6, the company presented post hoc analyses from several semaglutide trials.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals